Avrobio Inc Expected To Post A Loss Of 55 Cents A Share: Earnings Preview

Tectonic Therapeutic

04/11/2022 19:37

* AVROBIO Inc  AVRO.OQ   AVRO.O  is expected to show no
change in
quarterly revenue when it reports  results on November 7
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for AVROBIO Inc is for
a loss
of 55 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for AVROBIO Inc
is
$4​, above​ its last closing price of $0.68. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.59       -0.57      -0.64     Missed  -11.8
 Mar. 31 2022  -0.58       -0.59      -0.68     Missed  -14.8
 Dec. 31 2021  -0.71       -0.74      -0.65     Beat    12.2​
 Sep. 30 2021  -0.75       -0.76      -0.75     Beat    1
 ​​Jun.        -0.66       -0.67      -0.74     Missed  -10.3
 30 2021                                                
 Mar. 31 2021  -0.77       -0.77      -0.65     Beat    15.3​
 Dec. 31 2020  -0.97       -0.90      -0.73     Beat    18.9
 Sep. 30 2020  -0.82       -0.80      -1.01     Missed  -25.7
 This summary was machine generated November 4 at 19:36 GMT.  All
figures in US dollars  unless otherwise stated